RE:RE:RE:RE:RE:SEC FilingsABOS indicated their $200M was sufficient to get through Phase 2.
A previous post by gold trader linked to a good analysis showing that a successful Ph2 product (better than preceding products) has a $21B valuation based on the size of the ALZ therapeutic market.
So getting through Phase 2 is the real challenge. If they do that successfully, the share price should surge and raising the last bit for Ph3 will be easy.
I think our position for raising the Phase 2 funds will be strengthened by the Phase 1 data, especially if ARIA-E is as low as they expect. Given that a meager $20M cost half of the company, we'll need a strong Phase 1 to get that next $150-$200M without diluting 10-fold or more.